Polyganics Extends Global Distribution Network with the Addition of Multiple US Distributors

Groningen, The Netherlands, 5 September 2017 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices to promote peripheral nerve reconstruction and regeneration, announces the appointment of six US distributors for its peripheral nerve repair (PNR) portfolio.

New agreements with Southern Orthopaedics, Medex Surgical, Rascher Medical Solutions, Med Rep Corporation, South Coast Orthopedics and OJI Surgical will provide regional distribution of Polyganics’ PNR portfolio, which includes its NEUROCAP®, NEUROLAC®, and VIVOSORB® products. The portfolio uses Polyganics’ patented bioresorbable polymers to support nerve repair and recovery following surgery or injury.

Southern Orthopaedics LLC will provide distribution services to South Carolina, Alabama and Georgia. Medex Surgical LLP will cover the southern states of Texas, New Mexico, Oklahoma, Arkansas and Louisiana. Rascher Medical Solutions Inc. will distribute to Illinois and Wisconsin, and Med Rep Corporation Inc. will provide distribution for the states of Virginia, Maryland, Washington DC, Pennsylvania and Delaware. South Coast Orthopedics will serve the Southern Florida region. Finally, OJI Surgical Inc. will serve the western states of Oregon, Washington and Idaho.

Launched in 2016, NEUROCAP® is an innovative treatment option for symptomatic end-neuromas, providing a great potential for revolutionizing the previous treatment options of complex surgery, which leaves many patients still in pain. NEUROCAP® achieves this by protecting the peripheral nerve end, separating it from the surrounding environment, in turn preventing further damage and pain from occurring. This new method enables surgeons to provide more effective therapy for their patients, which will now be accessible across the US in addition to in Europe. Early positive signals from multiple hand and plastic surgeons that are affiliated with prominent international institutes involved in the PROTECT study – a prospective cohort evaluation of the product’s performance – drive the adoption of the complete Polyganics PNR portfolio, including NEUROCAP®.

Rudy Mareel, CEO of Polyganics, said: “Our PNR products provide clinically approved solutions to complex and painful conditions that can arise following nerve injury. The expansion of our distribution network in the US is in response to a high demand for these products in the region, and will enable us to provide more efficient services across a large number of states.  The US additions follow distribution agreements in Western Europe with Orthomed (France), Tapmed (Germany) and Osteotec (UK). Alongside our rapidly growing global distributor network, the continued momentum of our PNR portfolio is also demonstrated by the recent approval of NEUROCAP® in Australia.”

Greg Broms, CEO of Southern Orthopaedics, said: “Healthy nerve repair is vital to ensuring an easy and full recovery following surgery, and Polyganic’s advanced polymer technology will enable us to provide the best possible care to our patients. The adoption of Polyganics’ PNR products is part of a larger initiative we have underway to expand our portfolio and be able to offer the latest technologies available in orthopedic surgery.”

Keith Barcal, CEO of Med Rep Corporation, said: “It’s important to be able to provide high-tech, quality products to physicians, and so Polyganics’ peripheral nerve repair portfolio is an ideal fit for us. We’re hugely supportive of the work Polyganics is doing to further the field of nerve repair, and we’re delighted to be able to play a part in its distribution.”

Contact details for Polyganic’s US distributors are available here: http://polyganics.com/partners/distributors

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

Polyganics’ portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. In the Peripheral Nerve Repair (PNR) and neurosurgery field, the portfolio includes three marketed products: VIVOSORB® for minimizing unwanted tissue adhesions after surgery; NEUROLAC® for supporting PNR following hand surgery; and NEUROCAP® for the management of symptomatic neuromas. Products in development include a sealant for the dura membrane, for use in post brain surgery.

In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE®) to US Company Stryker, one of the world’s leading medical technology companies. NASOPORE®, a reliable, easy-to-use, nasal wound care dressing made of biodegradable foam, has been used in over 3.5m procedures globally. Polyganics continues to manufacture the NASOPORE® product range for Stryker.

Polyganics is profitable and privately held. The Company is based in Groningen, The Netherlands, a center of biomedical engineering excellence, in an ISO 13485-certified manufacturing facility. The Company’s polymer platform technologies are protected by a broad portfolio of patents and its products have received clearance from the US FDA, CE-approval, and approval from CFDA and other international authorities.

For more information, visit: www.polyganics.com